BRPI0923341A2 - oligonucleotideos imunoestimuladores - Google Patents
oligonucleotideos imunoestimuladoresInfo
- Publication number
- BRPI0923341A2 BRPI0923341A2 BRPI0923341-5A BRPI0923341A BRPI0923341A2 BR PI0923341 A2 BRPI0923341 A2 BR PI0923341A2 BR PI0923341 A BRPI0923341 A BR PI0923341A BR PI0923341 A2 BRPI0923341 A2 BR PI0923341A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunostimulatory oligonucleotides
- immunostimulatory
- oligonucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12102208P | 2008-12-09 | 2008-12-09 | |
| US61/121.022 | 2008-12-09 | ||
| US18179909P | 2009-05-28 | 2009-05-28 | |
| US61/181.799 | 2009-05-28 | ||
| PCT/IB2009/055444 WO2010067262A1 (en) | 2008-12-09 | 2009-12-01 | Immunostimulatory oligonucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0923341A2 true BRPI0923341A2 (pt) | 2018-05-29 |
| BRPI0923341B1 BRPI0923341B1 (pt) | 2021-04-06 |
| BRPI0923341B8 BRPI0923341B8 (pt) | 2021-05-25 |
Family
ID=41716468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0923341A BRPI0923341B8 (pt) | 2008-12-09 | 2009-12-01 | oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9453059B2 (pt) |
| EP (2) | EP2376107B1 (pt) |
| JP (1) | JP5016733B2 (pt) |
| KR (1) | KR101329374B1 (pt) |
| CN (1) | CN102333538B (pt) |
| AR (1) | AR074501A1 (pt) |
| AU (1) | AU2009325926B2 (pt) |
| BR (1) | BRPI0923341B8 (pt) |
| CA (1) | CA2745096C (pt) |
| CO (1) | CO6382137A2 (pt) |
| DK (2) | DK2376107T3 (pt) |
| ES (2) | ES2481040T3 (pt) |
| HK (1) | HK1165325A1 (pt) |
| HU (1) | HUE027823T2 (pt) |
| IL (1) | IL213162A (pt) |
| MX (1) | MX2011006088A (pt) |
| MY (2) | MY172421A (pt) |
| NZ (1) | NZ593220A (pt) |
| PE (1) | PE20110998A1 (pt) |
| PL (2) | PL2376107T3 (pt) |
| PT (1) | PT2376107E (pt) |
| RU (2) | RU2477753C2 (pt) |
| SG (1) | SG171829A1 (pt) |
| SI (2) | SI2759306T1 (pt) |
| TW (1) | TWI370740B (pt) |
| WO (1) | WO2010067262A1 (pt) |
| ZA (1) | ZA201104048B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ593220A (en) * | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
| SI2699587T1 (sl) | 2011-04-22 | 2019-08-30 | Wyeth Llc | Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka |
| SG10201610251PA (en) | 2012-06-08 | 2017-01-27 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SG10201704611WA (en) | 2012-12-13 | 2017-07-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| SG11201507462QA (en) * | 2013-03-14 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| BR112015027327B1 (pt) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| AU2014268836B2 (en) | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| AR097029A1 (es) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
| WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
| MY178288A (en) | 2013-09-20 | 2020-10-07 | Nat Inst Biomedical Innovation Health & Nutrition | Complex containing oligonucleotide having immunopotentiating activity and use thereof |
| CN105925583B (zh) * | 2013-11-08 | 2019-05-17 | 上海交通大学 | 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途 |
| CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
| JP2017537619A (ja) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | 球状核酸ナノ粒子複合体の配列特異的細胞内取込 |
| AU2016332266B2 (en) * | 2015-09-30 | 2020-05-07 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
| KR20210068601A (ko) * | 2016-06-02 | 2021-06-09 | 조에티스 서비시즈 엘엘씨 | 감염성 기관지염에 대한 백신 |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| AU2018313636A1 (en) * | 2017-08-10 | 2020-03-26 | Yisheng Biopharma (Singapore) Pte Ltd | A composition for treating and/or preventing hepatitis B virus infection and the use thereof |
| CN111629750A (zh) | 2017-09-28 | 2020-09-04 | 辉瑞公司 | 用于引发针对艰难梭菌的免疫应答的组合物和方法 |
| EP3946444A1 (en) | 2019-04-01 | 2022-02-09 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
| AU2020403296A1 (en) * | 2019-12-13 | 2022-07-07 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Immunostimulatory composition and use thereof |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| CN112877275B (zh) * | 2021-02-04 | 2023-03-31 | 中国农业科学院兰州兽医研究所 | Hdac2基因敲除的bhk-21细胞系及其构建方法和应用 |
| CN115252772A (zh) * | 2021-04-30 | 2022-11-01 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
| TWI802177B (zh) * | 2021-12-27 | 2023-05-11 | 景岳生物科技股份有限公司 | 副乾酪乳桿菌gmnl-32之核苷酸用於製備調節免疫能力之醫藥組合物的用途 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| WO1999013676A2 (en) | 1997-09-12 | 1999-03-18 | Williams Wireless, Inc. | Wide area telemetry network |
| US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
| ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| EP1733735B1 (en) * | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
| SE9801923D0 (sv) * | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
| US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
| AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| ES2299520T3 (es) * | 2000-09-01 | 2008-06-01 | Epigenomics Ag | Procedimiento para la determinacion del grado de metilacion de determinadas citosinas en dna genomico en el contexto secuencial 5'-cpg-3'. |
| GB0031079D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Vaccine |
| US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| EP2423335B1 (en) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
| AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
| DK1450856T3 (da) * | 2001-09-14 | 2010-05-31 | Cytos Biotechnology Ag | Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse |
| US7514415B2 (en) | 2002-08-01 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
| US7514414B2 (en) | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| AU2003213140A1 (en) * | 2002-03-01 | 2003-10-13 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
| US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| US7758876B2 (en) | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| CA2511538C (en) | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
| AU2004226605A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| CN101454451A (zh) * | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | 具有增强免疫刺激能力的c类寡核苷酸类似物 |
| KR101138131B1 (ko) * | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
| CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US20060111271A1 (en) * | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
| US20060153844A1 (en) | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| JP2008535859A (ja) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
| JP5481068B2 (ja) | 2005-08-31 | 2014-04-23 | アメリカ合衆国 | ＣｐＧオリゴデオキシヌクレオチドによって誘発される免疫応答を変化させる方法 |
| WO2007064478A2 (en) | 2005-11-28 | 2007-06-07 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
| MX2008013993A (es) | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
| SI2484375T1 (en) | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | A vaccine composition comprising a synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| MX2009005849A (es) | 2006-12-04 | 2009-08-12 | Univ Illinois | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. |
| US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| CA2713879C (en) * | 2008-02-01 | 2020-01-07 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
| WO2009149252A1 (en) * | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
| US8728465B2 (en) | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| NZ727616A (en) | 2008-06-27 | 2018-06-29 | Zoetis Services Llc | Novel adjuvant compositions |
| US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8053422B2 (en) | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
| SG10201400388QA (en) | 2008-12-09 | 2014-05-29 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
| NZ593220A (en) * | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
| US8552165B2 (en) | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
| EP2424562B1 (en) * | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| AU2010254550B2 (en) * | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
| SG177637A1 (en) | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| US20110064750A1 (en) * | 2009-07-31 | 2011-03-17 | Nabi Biopharmaceuticals | Method and kit for treating nicotine addiction |
| SG10201401516XA (en) | 2009-09-03 | 2014-10-30 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| JP2011092108A (ja) | 2009-10-30 | 2011-05-12 | Rikkyo Gakuin | シアニジウム類由来のプロトンａｔｐアーゼ遺伝子を用いた耐性植物体の作出方法及び該遺伝子の用途 |
| AU2011258156B2 (en) * | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
| AU2011259718B2 (en) * | 2010-05-28 | 2016-03-03 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules |
| TWI455722B (zh) * | 2010-06-04 | 2014-10-11 | Pfizer Vaccines Llc | 用於預防或治療菸鹼成癮之共軛體 |
| EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| SI2699587T1 (sl) * | 2011-04-22 | 2019-08-30 | Wyeth Llc | Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka |
| CN104080479B (zh) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
| US20150017201A1 (en) * | 2013-03-15 | 2015-01-15 | Regents Of The University Of Minnesota | Novel nicotine dna vaccines |
-
2009
- 2009-12-01 NZ NZ593220A patent/NZ593220A/xx not_active IP Right Cessation
- 2009-12-01 CA CA2745096A patent/CA2745096C/en active Active
- 2009-12-01 RU RU2011122418/10A patent/RU2477753C2/ru active
- 2009-12-01 EP EP09774978.2A patent/EP2376107B1/en active Active
- 2009-12-01 PL PL09774978T patent/PL2376107T3/pl unknown
- 2009-12-01 ES ES09774978.2T patent/ES2481040T3/es active Active
- 2009-12-01 BR BRPI0923341A patent/BRPI0923341B8/pt not_active IP Right Cessation
- 2009-12-01 DK DK09774978.2T patent/DK2376107T3/da active
- 2009-12-01 MX MX2011006088A patent/MX2011006088A/es active IP Right Grant
- 2009-12-01 MY MYPI2015000983A patent/MY172421A/en unknown
- 2009-12-01 JP JP2011540283A patent/JP5016733B2/ja active Active
- 2009-12-01 SI SI200931411A patent/SI2759306T1/sl unknown
- 2009-12-01 MY MYPI2011002378A patent/MY160201A/en unknown
- 2009-12-01 PL PL14161886.8T patent/PL2759306T3/pl unknown
- 2009-12-01 KR KR1020117015657A patent/KR101329374B1/ko active IP Right Grant
- 2009-12-01 SI SI200930939T patent/SI2376107T1/sl unknown
- 2009-12-01 ES ES14161886.8T patent/ES2572563T3/es active Active
- 2009-12-01 EP EP14161886.8A patent/EP2759306B1/en active Active
- 2009-12-01 AU AU2009325926A patent/AU2009325926B2/en not_active Ceased
- 2009-12-01 PE PE2011001201A patent/PE20110998A1/es active IP Right Grant
- 2009-12-01 HU HUE14161886A patent/HUE027823T2/hu unknown
- 2009-12-01 WO PCT/IB2009/055444 patent/WO2010067262A1/en active Application Filing
- 2009-12-01 DK DK14161886.8T patent/DK2759306T3/en active
- 2009-12-01 CN CN200980149607.3A patent/CN102333538B/zh not_active Expired - Fee Related
- 2009-12-01 PT PT97749782T patent/PT2376107E/pt unknown
- 2009-12-01 SG SG2011038270A patent/SG171829A1/en unknown
- 2009-12-07 AR ARP090104733A patent/AR074501A1/es active IP Right Grant
- 2009-12-08 TW TW098141948A patent/TWI370740B/zh not_active IP Right Cessation
-
2011
- 2011-05-26 IL IL213162A patent/IL213162A/en active IP Right Grant
- 2011-05-31 ZA ZA2011/04048A patent/ZA201104048B/en unknown
- 2011-06-10 CO CO11072590A patent/CO6382137A2/es active IP Right Grant
-
2012
- 2012-06-27 HK HK12106265.1A patent/HK1165325A1/xx not_active IP Right Cessation
- 2012-11-27 RU RU2012150453A patent/RU2610690C2/ru active
-
2013
- 2013-06-28 US US13/930,213 patent/US9453059B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2376107T3 (da) | Immunstimulerende oligonukleotider | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| DK2342317T3 (da) | Hængende-dråbe-plade | |
| DE602009000234D1 (de) | msignals | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| DE602008003972D1 (de) | Sitzrücklehnungsmechanismus | |
| DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
| DK2336132T3 (da) | Morpholinpurinderivat | |
| DK2335031T3 (da) | In-line-måler | |
| DK2300238T3 (da) | Skyggebillede-sikkerhedstræk | |
| DE602008003970D1 (de) | Strahlstromkalibriersystem | |
| DK2271613T3 (da) | Hydroxymethylcyklohexylaminer | |
| BRPI0915562A2 (pt) | tamis melhorado | |
| BRPI0915442A2 (pt) | tamis melhorado | |
| BRPI0907522A2 (pt) | biarlamidas | |
| DE112009001946A5 (de) | Mobelauszugsführung | |
| DE602009000488D1 (de) | Obstvereinzelvorrichtung | |
| BRPI0907863A2 (pt) | pirrolopirimidinacarboxamidas | |
| BRPI0909634A2 (pt) | 2-aminoquinolinas | |
| DE112009000183A5 (de) | Sicherheitsvorreiber | |
| BRPI0909637A2 (pt) | 2-aminoquinolinas | |
| DE602009000862D1 (de) | Gehwagenbremse | |
| AT507449A3 (de) | Dämmstoffbefestiger | |
| DK2254963T3 (da) | Kerne-skal-flowforbedrer | |
| DE602009001190D1 (de) | Gleichstromumrichtervorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |